| ŠTEFÁNIK, Michal, James J. VALDES, Fortunatus C. EZEBUO, Jan HAVIERNIK, Ikemefuna C. UZOCHUKWU, Martina FOJTÍKOVÁ, Jiří SALÁT, Luděk EYER a Daniel RŮŽEK. FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms. Basel: MDPI, 2020, roč. 8, č. 4, s. 1-17. ISSN 2076-2607. Dostupné z: https://dx.doi.org/10.3390/microorganisms8040599. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1661516,
author = {Štefánik, Michal and Valdes, James J. and Ezebuo, Fortunatus C. and Haviernik, Jan and Uzochukwu, Ikemefuna C. and Fojtíková, Martina and Salát, Jiří and Eyer, Luděk and Růžek, Daniel},
article_location = {Basel},
article_number = {4},
doi = {http://dx.doi.org/10.3390/microorganisms8040599},
keywords = {FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral},
language = {eng},
issn = {2076-2607},
journal = {Microorganisms},
title = {FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells},
url = {https://doi.org/10.3390/microorganisms8040599},
volume = {8},
year = {2020}
}
TY - JOUR
ID - 1661516
AU - Štefánik, Michal - Valdes, James J. - Ezebuo, Fortunatus C. - Haviernik, Jan - Uzochukwu, Ikemefuna C. - Fojtíková, Martina - Salát, Jiří - Eyer, Luděk - Růžek, Daniel
PY - 2020
TI - FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
JF - Microorganisms
VL - 8
IS - 4
SP - 1-17
EP - 1-17
PB - MDPI
SN - 20762607
KW - FDA
KW - flavivirus
KW - Zika virus
KW - tick-borne encephalitis virus
KW - West Nile virus
KW - antiviral
UR - https://doi.org/10.3390/microorganisms8040599
L2 - https://doi.org/10.3390/microorganisms8040599
N2 - Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.
ER -
ŠTEFÁNIK, Michal, James J. VALDES, Fortunatus C. EZEBUO, Jan HAVIERNIK, Ikemefuna C. UZOCHUKWU, Martina FOJTÍKOVÁ, Jiří SALÁT, Luděk EYER a Daniel RŮŽEK. FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. \textit{Microorganisms}. Basel: MDPI, 2020, roč.~8, č.~4, s.~1-17. ISSN~2076-2607. Dostupné z: https://dx.doi.org/10.3390/microorganisms8040599.
|
